Terns Pharmaceuticals Stock Soars Over 40% After Leukemia Drug Delivers Strong Early Responses

Terns Pharmaceuticals shares surged over 40% following the release of additional positive Phase 1 data for its chronic myeloid leukemia (CML) therapy, TERN-701. The updated results from the CARDINAL trial demonstrated a high major molecular response (MMR) rate and the treatment continued to show an encouraging safety profile, supporting its advancement to Phase 2.